文献速递浆细胞疾病造血干细胞移植与细胞治疗

自体造血干细胞移植对比硼替佐米-美法仑-泼尼松方案,联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗及来那度胺维持治疗用于新诊断多发性骨髓瘤(EMN02/HO95):一项多中心、随机、开放标签、3期研究

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
PubMed 文献 · Lancet Haematol · 2020-04-30

该研究纳入1503例新诊断多发性骨髓瘤患者,首次随机比较自体HSCT与VMP强化治疗,第二次随机比较VRD巩固与无巩固。中位随访60.3个月,自体HSCT较VMP显著改善中位PFS(56.7 vs 41.9个月,HR 0.73)。VRD巩固较无巩固显著改善中位PFS(58.9 vs 45.5个月,HR 0.77)。

要点

  • 自体HSCT较VMP显著改善中位PFS(56.7 vs 41.9个月,HR 0.73,p=0.0001)。
  • VRD巩固较无巩固显著改善中位PFS(58.9 vs 45.5个月,HR 0.77,p=0.014)。
  • 自体HSCT组≥3级中性粒细胞减少79% vs VMP组29%,血小板减少83% vs 16%。

核心结论

  • 研究支持在新诊断多发性骨髓瘤中使用自体HSCT作为强化治疗以及使用巩固治疗,即使在新药时代也是如此。
  • 未来研究需重新评估大剂量化疗的作用,特别是在含单克隆抗体联合免疫调节剂和蛋白酶体抑制剂加地塞米松的四药诱导方案后达到不可检测微小残留病的患者中。

研究设计与样本

  • 随机、开放标签、3期研究,在欧洲骨髓瘤网络172个学术和社区实践中心招募既往未经治疗的多发性骨髓瘤患者。
  • 入组标准:年龄18-65岁,国际分期系统(ISS)1-3期症状性多发性骨髓瘤,可测量疾病(血清M蛋白>10 g/L或24小时尿M蛋白>200 mg或异常游离轻链比值且受累游离轻链>100 mg/L,或活检证实浆细胞瘤),WHO体能状态0-2级(继发于骨髓瘤的3级允许)。
  • 首次随机(1:1)接受四个42天周期的硼替佐米(1.3 mg/m2,静脉或皮下,第1、4、8、11、22、25、29、32天)联合美法仑(9 mg/m2,口服,第1-4天)和泼尼松(60 mg/m2,口服,第1-4天)或大剂量美法仑(200 mg/m2)后自体HSCT,按中心和ISS疾病分期分层;在有双次HSCT政策的中心,首次随机(1:1:1)为VMP或单次或双次HSCT。
  • 随后第二次随机分配接受两个28天周期的VRD巩固治疗(硼替佐米1.3 mg/m2静脉或皮下第1、4、8、11天;来那度胺25 mg口服第1-21天;地塞米松20 mg口服第1、2、4、5、8、9、11、12天)或无巩固;两组均接受来那度胺维持治疗(10 mg口服,28天周期第1-21天)。
  • 主要结局为首次和第二次随机后的无进展生存期,在意向治疗人群中分析;安全性分析包括所有接受至少一剂研究药物的患者。

主要发现

  • 中位随访60.3个月(IQR 52.2-67.6),自体HSCT组中位PFS为56.7个月(95% CI 49.3-64.5),VMP组为41.9个月(37.5-46.9),HR 0.73(0.62-0.85),p=0.0001。
  • 中位随访42.1个月(IQR 32.3-49.2),VRD巩固组中位PFS为58.9个月(54.0-不可估计),无巩固组为45.5个月(39.5-58.4),HR 0.77(0.63-0.95),p=0.014。
  • 自体HSCT组对比VMP组最常见的≥3级不良事件包括中性粒细胞减少(513/652例[79%] vs 137/472例[29%])、血小板减少(541例[83%] vs 74例[16%])、胃肠道疾病(80例[12%] vs 25例[5%])和感染(192例[30%] vs 18例[4%])。
  • 自体HSCT组702例中239例(34%)和VMP组495例中135例(27%)发生至少一次严重不良事件;感染是各组最常见的严重不良事件(206/368例[56%]和70/189例[37%])。
  • 首次随机后的311例死亡中38例(12%)可能与治疗相关:自体HSCT组26例(68%),VMP组12例(32%);最常见原因为感染(8例[21%])、心脏事件(6例[16%])和第二原发恶性肿瘤(20例[53%])。

临床怎么用

  • 作者认为,本研究支持在新诊断多发性骨髓瘤中使用自体HSCT作为强化治疗以及使用巩固治疗,即使在新药时代也是如此。
  • 作者建议,未来研究需重新评估大剂量化疗的作用,特别是在含单克隆抗体联合免疫调节剂和蛋白酶体抑制剂加地塞米松的四药诱导方案后达到不可检测微小残留病的患者中。

局限性

  • 第二次随机分析时,数据截止时进展或死亡事件数低于最终分析预先计划的事件数,因此报告的是方案规定的第二次中期分析结果(达到66%事件时,数据截止日期2018年1月18日)。
  • 作者指出未来研究需重新评估大剂量化疗的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation. METHODS: In this randomised, open-label, phase 3 study we recruited previously untreated patients with multiple myeloma at 172 academic and community practice centres of the European Myeloma Network. Eligible patients were aged 18-65 years, had symptomatic multiple myeloma stage 1-3 according to the International Staging System (ISS), measurable disease (serum M protein >10 g/L or urine M protein >200 mg in 24 h or abnormal free light chain [FLC] ratio with involved FLC >100 mg/L, or proven plasmacytoma by biopsy), and WHO performance status grade 0-2 (grade 3 was allowed if secondary to myeloma). Patients were first randomly assigned (1:1) to receive either four 42-day cycles of bortezomib (1·3 mg/m2 administered intravenously or subcutaneously on days 1, 4, 8, 11, 22, 25, 29, and 32) combined with melphalan (9 mg/m2 administered orally on days 1-4) and prednisone (60 mg/m2 administered orally on days 1-4) or autologous HSCT after high-dose melphalan (200 mg/m2), stratified by site and ISS disease stage. In centres with a double HSCT policy, the first randomisation (1:1:1) was to VMP or single or double HSCT. Afterwards, a second randomisation assigned patients to receive two 28-day cycles of consolidation therapy with bortezomib (1·3 mg/m2 either intravenously or subcutaneously on days 1, 4, 8, and 11), lenalidomide (25 mg orally on days 1-21), and dexamethasone (20 mg orally on days 1, 2, 4, 5, 8, 9, 11, and 12) or no consolidation; both groups received lenalidomide maintenance therapy (10 mg orally on days 1-21 of a 28-day cycle). The primary outcomes were progression-free survival from the first and second randomisations, analysed in the intention-to-treat population, which included all patients who underwent each randomisation. All patients who received at least one dose of study drugs were included in the safety analyses. This study is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov (NCT01208766), and has completed recruitment. FINDINGS: Between Feb 25, 2011, and April 3, 2014, 1503 patients were enrolled. 1197 patients were eligible for the first randomisation, of whom 702 were assigned to autologous HSCT and 495 to VMP; 877 patients who were eligible for the first randomisation underwent the second randomisation to VRD consolidation (n=449) or no consolidation (n=428). The data cutoff date for the current analysis was Nov 26, 2018. At a median follow-up of 60·3 months (IQR 52·2-67·6), median progression-free survival was significantly improved with autologous HSCT compared with VMP (56·7 months [95% CI 49·3-64·5] vs 41·9 months [37·5-46·9]; hazard ratio [HR] 0·73, 0·62-0·85; p=0·0001). For the second randomisation, the number of events of progression or death at data cutoff was lower than that preplanned for the final analysis; therefore, the results from the second protocol-specified interim analysis, when 66% of events were reached, are reported (data cutoff Jan 18, 2018). At a median follow-up of 42·1 months (IQR 32·3-49·2), consolidation therapy with VRD significantly improved median progression-free survival compared with no consolidation (58·9 months [54·0-not estimable] vs 45·5 months [39·5-58·4]; HR 0·77, 0·63-0·95; p=0·014). The most common grade ≥3 adverse events in the autologous HSCT group compared to the VMP group included neutropenia (513 [79%] of 652 patients vs 137 [29%] of 472 patients), thrombocytopenia (541 [83%] vs 74 [16%]), gastrointestinal disorders (80 [12%] vs 25 [5%]), and infections (192 [30%] vs 18 [4%]). 239 (34%) of 702 patients in the autologous HSCT group and 135 (27%) of 495 in the VMP group had at least one serious adverse event. Infection was the most common serious adverse event in each of the treatment groups (206 [56%] of 368 and 70 [37%] of 189). 38 (12%) of 311 deaths from first randomisation were likely to be treatment related: 26 (68%) in the autologous HSCT group and 12 (32%) in the VMP group, most frequently due to infections (eight [21%]), cardiac events (six [16%]), and second primary malignancies (20 [53%]). INTERPRETATION: This study supports the use of autologous HSCT as intensification therapy and the use of consolidation therapy in patients with newly diagnosed multiple myeloma, even in the era of novel agents. The role of high-dose chemotherapy needs to be reassessed in future studies, in particular in patients with undetectable minimal residual disease after four-drug induction regimens including a monoclonal antiboby combined with an immunomodulatory agent and a proteasome inhibitor plus dexamethasone. FUNDING: Janssen and Celgene.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020. PMID: 32359506. doi:10.1016/S2352-3026(20)30099-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。